放射敏感性肿瘤自杀基因载体的构建及其对宫颈癌杀伤作用的研究
|
摘要
目的 构建可被放射线激活而转录的早期生长反应因子-1(Egr-1)启动子驱动的双自杀基因CDTK重组真核表达载体(pcDNA3.1-CMV-Egr-1-CDTK)；将其转染人宫颈癌细胞株Hela细胞，在~(60)C_O-γ射线照射后，研究其在宫颈癌细胞中的表达及在前体药物5-FU和GCV作用下体外对宫颈癌细胞的杀伤作用及旁观者效用；同时将转染了重组真核表达载体(pcDNA3.1-CMV-Egr-1-CDTK)的人宫颈癌细胞种植于Balb／c裸鼠皮下，建立裸鼠宫颈癌种植瘤模型，研究放射线诱导性自杀基因在射线作用下对体内宫颈癌的治疗作用。
方法 利用PCR扩增CD，TK基因，并将其构建成融合基因，连至pc DNA3.1质粒载体上，从家鼠基因组中扩增Egr-1启动子序列，并扩增CMV增强子插入Egr-1启动子构建成真核表达载体pcDNA3.1-CMV-Egr-1-CDTK。体外培养人宫颈癌细胞株Hela细胞，将真核表达载体pcDNA3.1-CMV-Egr-1-CDTK通过电转染方法转染人宫颈癌细胞hela细胞株，经放射线~(60)CO-γ照射并给予前体药物，通过RT-PCR，Western等方法检测转染细胞中融合基因CDTK的表达情况，MTT法检测细胞存活比率来评价我们构建的肿瘤自杀基因载体对Hela细胞的杀伤效应和旁观者效应以及对放射治疗的增敏性。将转染肿瘤自杀基因载体阳性的Hela细胞进行裸鼠体内致瘤，了解致瘤特性，在前体药物和放射线~(60)C_O-γ照射的不同组合治疗条件下，测量肿瘤大小，进行肿瘤组织病理切片检查，同时RT-PCR检测肿瘤组织内CDTK扩增片段。
结果 真核表达载体质粒经酶切和测序鉴定证明其方向正确。真核表达载体质粒转染Hela细胞，筛选后得到表达CDTK基因的Hela／CDTK细胞，RT-PCR显示长度为400bp的阳性条带，Western杂交技术检测结果可见一59KD大小的蛋白质，与CDTK基因序列分析的预期大小一致，证明该载体在Hela细胞能被转录和翻译成CDTK融合蛋白。MTT检测发现，转染pcDNA3.1-CMV-Egr-1-CDTK的细胞对放射线~(60)C_O-γ照射的敏感性明显增强。分组动物试验时，治疗前五组动物瘤体大小无差异，治疗的最后一天，阳性细胞瘤+前体药物+放射组肿瘤体积最小，与阳性细胞瘤+放射组肿瘤有显著性差异(P＜0.05)，与阳性细胞瘤+PBS组肿瘤有极显著性差异(P＜0.01)。转染阳性细胞组病理检查细胞有大量坏死和溶解，对照组则可见细胞排列紧密未
Objective Recombinant plasmid vector pcDNA3.1-CMV-Egr-1-CDTK was constructed by fusing of early growth respons-1(Egr-1) promoter to the double suicide gene CDTK gene; To transfer human cervical cancer cell lines (Hela) with recombinant plasmid vector pcDNA3.1-CMV-Egr-1-CDTK,after irradiated by ~(60)Co-γ rays ,the CDTK mRNA expression in the transfected cell line and the killing effects and the by-stander killing effects in vitro of double suicide genes on the cell lines were observed; The animal model of Balb/c nude mice was established by injected subcutaneously with exponentially growing transfected cell lines for further research of the killing effect on cervical cancer in vivo by radio-induced suicide gene after exposure to ~(60)Co-γ rays.
Methods The CDTk gene were amplified with polymerase chain reaction (PCR) technique and were fused into CDTK gene, linked with plasmid vector pcDNA3.1, Egr-1 promotor and CMV enhancer were amplified and then inserted CMV enhance infront of Egr-1, aquired plasmid vector pcDNA3.1-CMV-Egr-1-CDTK. Which were transfected into cervical cancer cell lines with electroblot as a delivery system. After accepted with ~(60)Co-r rays irradiation, prodrugs(5-FC,GCV) was used in the cells ,RT-PCR, Western blot analysis were used to determine the CDTK mRNA expression in Hela cells which had been transfected by pcDNA3.1-CMV-Egr-1-CDTK plasmid vector. The viabilitys of cells were determined by the method of MTT .For the purpose ,we can research the killing effect and the by-stander killing effect of radio-induced double suicide gene on the cervical cancer cell lines in vitro and the sensitization to irradiation. The Balb/c nude mice were injected subcutaneously with pcDNA3.1-CMV-Egr-1-CDTK. The tumorigenesis characteristic were obtained. The animals were devided into five groups and after the therapy of irradiation and prodrugs respectively, the volume of tumor were observed. Furthermore, the pathological results of tumor was observed. At the same time, RT-PCR was used to detect the tumors CDTK amplification fragements.
Results The successful construction of recombinant plasmid vector was certificated through enzyme cutting and sequencing. The length of Hela/CDTK gene was certificated by RT-PCR and Western blot, a 59KD protein was obtaind which was equal to the expection of CDTK gene sequencing. So proved the recombinant plasmid
方法 利用PCR扩增CD，TK基因，并将其构建成融合基因，连至pc DNA3.1质粒载体上，从家鼠基因组中扩增Egr-1启动子序列，并扩增CMV增强子插入Egr-1启动子构建成真核表达载体pcDNA3.1-CMV-Egr-1-CDTK。体外培养人宫颈癌细胞株Hela细胞，将真核表达载体pcDNA3.1-CMV-Egr-1-CDTK通过电转染方法转染人宫颈癌细胞hela细胞株，经放射线~(60)CO-γ照射并给予前体药物，通过RT-PCR，Western等方法检测转染细胞中融合基因CDTK的表达情况，MTT法检测细胞存活比率来评价我们构建的肿瘤自杀基因载体对Hela细胞的杀伤效应和旁观者效应以及对放射治疗的增敏性。将转染肿瘤自杀基因载体阳性的Hela细胞进行裸鼠体内致瘤，了解致瘤特性，在前体药物和放射线~(60)C_O-γ照射的不同组合治疗条件下，测量肿瘤大小，进行肿瘤组织病理切片检查，同时RT-PCR检测肿瘤组织内CDTK扩增片段。
结果 真核表达载体质粒经酶切和测序鉴定证明其方向正确。真核表达载体质粒转染Hela细胞，筛选后得到表达CDTK基因的Hela／CDTK细胞，RT-PCR显示长度为400bp的阳性条带，Western杂交技术检测结果可见一59KD大小的蛋白质，与CDTK基因序列分析的预期大小一致，证明该载体在Hela细胞能被转录和翻译成CDTK融合蛋白。MTT检测发现，转染pcDNA3.1-CMV-Egr-1-CDTK的细胞对放射线~(60)C_O-γ照射的敏感性明显增强。分组动物试验时，治疗前五组动物瘤体大小无差异，治疗的最后一天，阳性细胞瘤+前体药物+放射组肿瘤体积最小，与阳性细胞瘤+放射组肿瘤有显著性差异(P＜0.05)，与阳性细胞瘤+PBS组肿瘤有极显著性差异(P＜0.01)。转染阳性细胞组病理检查细胞有大量坏死和溶解，对照组则可见细胞排列紧密未
Objective Recombinant plasmid vector pcDNA3.1-CMV-Egr-1-CDTK was constructed by fusing of early growth respons-1(Egr-1) promoter to the double suicide gene CDTK gene; To transfer human cervical cancer cell lines (Hela) with recombinant plasmid vector pcDNA3.1-CMV-Egr-1-CDTK,after irradiated by ~(60)Co-γ rays ,the CDTK mRNA expression in the transfected cell line and the killing effects and the by-stander killing effects in vitro of double suicide genes on the cell lines were observed; The animal model of Balb/c nude mice was established by injected subcutaneously with exponentially growing transfected cell lines for further research of the killing effect on cervical cancer in vivo by radio-induced suicide gene after exposure to ~(60)Co-γ rays.
Methods The CDTk gene were amplified with polymerase chain reaction (PCR) technique and were fused into CDTK gene, linked with plasmid vector pcDNA3.1, Egr-1 promotor and CMV enhancer were amplified and then inserted CMV enhance infront of Egr-1, aquired plasmid vector pcDNA3.1-CMV-Egr-1-CDTK. Which were transfected into cervical cancer cell lines with electroblot as a delivery system. After accepted with ~(60)Co-r rays irradiation, prodrugs(5-FC,GCV) was used in the cells ,RT-PCR, Western blot analysis were used to determine the CDTK mRNA expression in Hela cells which had been transfected by pcDNA3.1-CMV-Egr-1-CDTK plasmid vector. The viabilitys of cells were determined by the method of MTT .For the purpose ,we can research the killing effect and the by-stander killing effect of radio-induced double suicide gene on the cervical cancer cell lines in vitro and the sensitization to irradiation. The Balb/c nude mice were injected subcutaneously with pcDNA3.1-CMV-Egr-1-CDTK. The tumorigenesis characteristic were obtained. The animals were devided into five groups and after the therapy of irradiation and prodrugs respectively, the volume of tumor were observed. Furthermore, the pathological results of tumor was observed. At the same time, RT-PCR was used to detect the tumors CDTK amplification fragements.
Results The successful construction of recombinant plasmid vector was certificated through enzyme cutting and sequencing. The length of Hela/CDTK gene was certificated by RT-PCR and Western blot, a 59KD protein was obtaind which was equal to the expection of CDTK gene sequencing. So proved the recombinant plasmid
引文
[1] 中国癌症预防与控制规划纲要(2003-2010)。
[2] Tanaka M, Inase N, Miyake S, et al. Neuron specific enolase promoter for suicide gene therapy in small cell lung carcinoma. Anti2 cancer Res, 2001, 21 (1A) : 2912294.
[3] Sethi N, Palefsky J. Treatment of human papillomavirus (HPV) type 162infected cells using herpes simplex virus type 1 thymidine kinase2mediated gene therapy transcriptionally regulated by the HPV E2 protein. Hum Gene Ther, 2003, 14 (1) : 45257.
[4] Hayasbi K, Hayashi T, Sun HD, et al. Contribution of a combination of ponicidin and acyclovir/ganciclovir to the antitumor efficacy of the herpes simplex virus thymidine kinase gene therapy system. Hum Gene Ther, 2002, 13 (3) : 4152423.
[5] Crystal RG, Hirschowitz E, Lieberman M, et al. Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum Gene Ther. 1997 May 20; 8 (8) : 985-1001.
[6] Scappaticci FA. Mechanisms and future directions for angiogesis2 based cancer therapies [J]. J Clin Oncol, 2002, 20 (18) : 39062 3927.
[7] Kokoris MS, Sabo P, Black ME. In vitro evaluation of mutant HSV-1 thymidine kinases for suicide gene therapy. Anticancer Res. 2000 Mar-Apr; 20 (2A) : 959-63
[8] Kokoris MS, Sabo P, Adman ET, et al. . Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant. Gene Ther. 1999 Aug; 6 (8) : 1415-26.
[9] Schwarzenberger P, Harrison L, Weinacker A, et al. The treatment of malignant mesothelioma with a gene modified cancer cell line: a phase I study. Hum Gene Ther. 1998 Nov 20; 9 (17) : 2641-9.
[10] 徐丛剑 张惜阴 金志军等；单纯疱疹病毒胸腺嘧啶核苷激酶基因／羟甲基无环鸟苷系统对人卵巢癌裸鼠网膜移植瘤的作用。中华妇产科杂志。1999，34(3)：165-167。
[11] Hoganson DK, Batra RK, Olsen JC, et al.. Comparison of the effects of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma. Cancer Res. 1996 Mar 15; 56 (6): 1315-23.
[12] Coustere C, Mentre F, Sommadossi JP, et al. A mathematical model of the kinetics of 5-fluorouracil and its metabolites in cancer patients. Cancer Chemother Pharmacol. 1991; 28(2):123-9.
[13] Joki T, Nakamura M, Ohno T. Activation of the radiosensitive EGR-1 promoter induces expression of the herpes simplex virus thymidine kinase gene and sensitivity of human glioma cells to ganciclovir. Hum Gene Ther 1995 Dec; 6(12):1507-13.
[14] Hanna E, Zhang X, Woodlis J, et al. Intramuscular electroporation delivery of IL-12 gene for treatment of squamous cell carcinoma located at distant site. Cancer Gene Ther. 2001 Mar;8(3):151-7.
[15] Corban-Wilhelm H, Hull WE, Becker G, et al. Cytosine deaminase and thymidine kinase gene therapy in a Dunning rat prostate tumour model: absence of bystander effects and characterisation of 5-fluorocytosine metabolism with 19F-NMR spectroscopy. Gene Ther. 2002 Dec; 9(23): 1564-75.
[16] Erbs P, Regulier E, Kintz J, et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res 2000 Jul 15; 60(14):3813-22
[17]Mullen CA, Kilstrup M, Blaese RM. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):33-7.
[18] Erbs P, Regulier E, Kintz J, et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res 2000 Jul 15; 60(14):3813-22
[19] Pow EH, McMillan AS, Leung WK, et al. Oral health condition in southern Chinese after radiotherapy for nasopharyngeal carcinoma: extent and nature of the problem. Oral Dis. 2003 Jul;9(4):196-202.
[20] Miyagi T, Koshida K, Hori 0, et al. Gene therapy for prostate cancer using the cytosine deaminase/uracil phosphoribosyltransferase suicide system. J Gene Med. 2003 Jan; 5 (1) : 30-7.
[21] Wang WJ, Tai CK, Kasahara N, et al. Highly efficient and tumor-restricted gene transfer to malignant gliomas by replication-competent retroviral vectors. Hum Gene Ther. 2003 Jan 20: 14 (2) : 117-27.
[22] 冯跃，赵军，黄盛东，等。CD、TK双自杀基因对消化道肿瘤细胞的体外抑制作用。中华国际医学杂志。2002，2 (4)：314-317
[23] Sung MW, Yeh HC, Thung SN, et al Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: results of a phase I clinical trial. Mol Ther. 2001 Sep; 4 (3) : 182-91.
[24] Griscelli F, Opolon P, Saulnier P, et al. Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients. Gene Ther. 2003 Mar; 10 (5) : 386-95.
[25] Xie Yunjie, Gilbert JD, Kim JH, et al. Efficacy of adenovirus-mediated CD/5-FC and HSV-1 thymidine kinase/ganciclovir suicide gene therapies concomitant with p53 gene therapy. Clin Cancer Res. 1999 Dec; 5 (12) : 4224-32.
[26] 刘晓霞，姜伟，姚明等GE7导入系统介导Ⅰ型单纯疱疹病毒胸腺嘧啶核苷激酶基因联合52FU治疗卵巢癌的研究。现代妇产科进展。2004，13 (6)：413-415。
[27] 姚远，彭芝兰，王和等。胞嘧啶脱氨酶基因联合52氟胞嘧啶对卵巢癌裸鼠移植瘤的抑制作用。中华妇产科杂志。2002，37 (4)：195-197。
[28] Kievit E, Bershad E, Ng E, et al. Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. Cancer Res. 1999 Apr 1; 59 (7) : 1417-21.
[29] Chung-Faye GA, Chen MJ, Green NK, et al. In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. Gene Ther. 2001 Oct; 8 (20) : 1547-54.
[30]. Erbs P, Regulier E, Kintz J, et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res. 2000 Jul 15; 60 (14) : 3813-22.
[31] Rogulski KR, Zhang K, Kolozsvary A, et al. Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy. Clin Cancer Res 1997 Nov; 3 (11) : 2081-8
[32] Sukhatme VP, Cao XM, Chang LC, et al. . A zinc finger-encoding gene coregulated with c-fos during growth and differentiation, and after cellular depolarization. Cell 1988 Apr 8; 53 (1) : 37-43
[33] Datta R, Rubin E, Sukhatme V, et al. . Ionizing radiation activates transcription of the EGR1 gene via CArG elements. Proc Natl Acad Sci U S A. 1992 Nov 1; 89 (21) : 10149-53.
[34]. Weichselbaum RR, Hallahan DE, Beckett MA, et al. Gene therapy targeted by radiation preferentially radiosensitizes tumor cells. Cancer Res. 1994 Aug 15; 54 (16) : 4266-9.
[35]. Kawashita Y, Ohtsuru A, Kaneda Y, et al. Regression of hepatocellular carcinoma in vitro and in vivo by radiosensitizing suicide gene therapy under the inducible and spatial control of radiation. Hum Gene Ther. 1999 Jun 10; 10 (9) : 1509-19.
[36] 魏道严，戴冰冰，陈诗书。放射诱导经Egr-1启动子调控的腺病毒介导CDglyTK基因的肿瘤靶向表达。中华医学杂志。2001，81 (16)：999-1003
[1] 林仲秋．宫颈癌治疗进展．广东医学，2004，25(2)：113-115
[2] 陈忠东，胡泳，曾宪端．卵巢移位及阴道延长术在宫颈癌治疗中的作用．中国 肿瘤临床，2000，27(4)：308-309．
[3] Sakuragi N, Takeda N, Hareyama H, etal. A multivariate analysis of blood vessel and lymph vessel invasion as predictors of ovarian and lymph mode metastases in patient with cervical carcinoma [J]. Cancer, 2000, 88: 2578-2583.
[4] Toman J, Feyereisl G, Zamecnik J, et al. A safe site for transpositation of ovaries in radical hysterectomy for cervical carcinoma [J]. Ceska Gynekol, 2001, 66: 184-186.
[5] 倪立洲．卵巢移植及功能保护在宫颈癌治疗中的作用探讨．现代中西医结合杂志，2005，14(15)：2035-2036．
[6] Pecorelli S. FIGO annual report on the results of treatment in gynecological cancer. (Vol. 23). Spain: BookPrint, SL, 1998. 5.
[7] 罗刚，郑成位，单锦露，等．~(252)锎中子腔内后装治疗宫颈癌的临床观察．中华妇产科杂志，2001，36(12)：742．
[8] Fellner C, Potter R, Knocke TH, et al. Comparison of radiography and computed tomography-based treatment planning in cervix cancer in brachytherapy with specific attention to some quality assurance aspects [J]. Radiother Oncl, 2001, 58 (1) : 53-62.
[9] Krempien RC, Daeuber S, Hensley FW, et al. Image fusion of CT and MRI data enables improved target volume definition in 3D-brachytherapy treatment planning[J], brachytherapy, 2003, 2 (3) : 164-171.
[10] Wachter-Gerstner N, Wachter S, Reinstadler E, et al. Bladder and rectum dose define from MRI based treatment planning for cervix cancer brachytherapy: comparison of dose-volume histograms for organ contours and organ wall, comparison with ICRU rectum and bladder reference point[J]. Radiother Oncol, 2003, 68 (3) : 269-276.
[11] Mutic S, Grigsby PW, Low DA, et al. PET-guided three-dimensional treatment planning of intracavitary gynecologic implants[J]. Int J Radiat Oncol Biol Phys, 2002, 52 (4) : 1104-1110.
[12] 刘德梅，朱向华．立体定向放射治疗宫颈癌的近期疗效观察．肿瘤研究与临床．2004，16(3)：207-208．
[13] 关玉兰，龙再秋，王伊洵．组织间插植放疗治疗外生型宫颈癌疗效探讨．中国实用妇科与产科杂志，2003，19(12)：745-746．
[14] Ferrandina G. Scambia G, Fagotti A, et al. Immunoradiometric and immunohistochemical analysis of Cathepsin D in ovarian cancer: lack of association with clinical outcome. Br J Cancer. 1998Dec, 78 (12) : 1645-52.
[15] Kim K, Chie EK, Wu HG, et al. Efficacy of paclitaxel and carboplatin as a regimen for postoperative concurrent chemoradiotherapy of high risk uterine cervix cancer. Gynecol Oncol, 2005 Dec, [Epub ahead of print].
[16] Borysiewicz LK, Fiander A, Nimako M, et al. A recombinant vaccinia virus encoding human papilloma virus types 16 and18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet, 1996, 347 (9014) : 1523.
[17] Van Driel WJ, Ressing ME, Kenter GG, et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of aphase Ⅰ～Ⅱ trial. EurJCancer, 1999, 35 (6) : 946.
[18] Muder spachL, Wilczynski S, Roman L, et al. A phase I trial of a human papillomavirus(HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV16 positive. ClinCancerRes, 2000, 6 (9) : 3406.
[19] Santin AD, Bellone S, Gokden M, et al. Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer. N Engl J Med, 2002, 346 (22) : 1752.
[20] Tanaka M, Inase N, Miyake S, et al. Neuron specific enolase promoter for suicide gene therapy in small cell lung carcinoma. Anti cancer Res, 2001, 21 (1A) : 291-294.
[21] Sethi N, Palefsky J. Treatment of human papilloma virus(HPV) type16-infected cells using herpes simplex virus typel thymidine kinase-mediated gene therapy transcriptionally regulated by the HPVE2 protein. HumGeneTher, 2003, 14 (1) : 45 57.
[22] Street D, Kaufmann AM, Vaughan A, et al. Interferon-gamma enhances susceptibility of cervical cancer cells to lysis by tumor-specific cytotoxic T cells. Gynecol Oncol, 1997, 65 (2) : 265 272.
[23] Ahn WS, Han YJ, Bae SM, et al. Differential suppression of human cervical cancer cell growth by adenovirus delivery of p53 in vitro: arrest phase of cell cycle is dependent on cell line. Jpn J Cancer Res, 2002, 93 (9) : 1012 1019.
[24] Buck AC, Shen C, Schirmeister H, et al. Liposomal delivery of antisene oliginucleotides for efficient down regulation of BCL2 and induced of apoptosis. Cancer Biother Radiopharm, 2003, 312 (3) : 585-591.
[25] 陈星，糜若然．反义治疗在宫颈癌中的研究．国外医学妇产科学分册，2005，32(4)：220-223．
[26] Kim HS, Shiraki K, Park SH. Expression of survivin in CIN and invasive squamous cell carcinoma of uterine cervix. Anticancer Res, 2002, 22 (2A) : 805-808.
[27] 王宏伟，陆志冲．电化学治疗宫颈癌32例观察报告．BIOMAGNETISM，2004，34-35．
[28] Green J, Kirwan J, Tiemey J, et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev. 2005 Jul 20; (3) : CD002225.
[29] Kim K, Chie EK, Wu HG, et al. Efficacy of paclitaxel and carboplatin as a regimen for postoperative concurrent chemoradiotherapy of high risk uterine cervix cancer. Gynecol Oncol. 2005 Dec 2; [Epub ahead of print].
[30] 黎婧琳．43℃微波热疗配合放射治疗宫颈癌的疗效观察．华夏医学，2004，6(17)：951-952．
[31] 耿进朝，张勇，李明山，等．超选择性TACE和静脉化疗治疗宫颈癌的临床应用．中国临床医学影像杂志，2004，15(3)：155-157．
[2] Tanaka M, Inase N, Miyake S, et al. Neuron specific enolase promoter for suicide gene therapy in small cell lung carcinoma. Anti2 cancer Res, 2001, 21 (1A) : 2912294.
[3] Sethi N, Palefsky J. Treatment of human papillomavirus (HPV) type 162infected cells using herpes simplex virus type 1 thymidine kinase2mediated gene therapy transcriptionally regulated by the HPV E2 protein. Hum Gene Ther, 2003, 14 (1) : 45257.
[4] Hayasbi K, Hayashi T, Sun HD, et al. Contribution of a combination of ponicidin and acyclovir/ganciclovir to the antitumor efficacy of the herpes simplex virus thymidine kinase gene therapy system. Hum Gene Ther, 2002, 13 (3) : 4152423.
[5] Crystal RG, Hirschowitz E, Lieberman M, et al. Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum Gene Ther. 1997 May 20; 8 (8) : 985-1001.
[6] Scappaticci FA. Mechanisms and future directions for angiogesis2 based cancer therapies [J]. J Clin Oncol, 2002, 20 (18) : 39062 3927.
[7] Kokoris MS, Sabo P, Black ME. In vitro evaluation of mutant HSV-1 thymidine kinases for suicide gene therapy. Anticancer Res. 2000 Mar-Apr; 20 (2A) : 959-63
[8] Kokoris MS, Sabo P, Adman ET, et al. . Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant. Gene Ther. 1999 Aug; 6 (8) : 1415-26.
[9] Schwarzenberger P, Harrison L, Weinacker A, et al. The treatment of malignant mesothelioma with a gene modified cancer cell line: a phase I study. Hum Gene Ther. 1998 Nov 20; 9 (17) : 2641-9.
[10] 徐丛剑 张惜阴 金志军等；单纯疱疹病毒胸腺嘧啶核苷激酶基因／羟甲基无环鸟苷系统对人卵巢癌裸鼠网膜移植瘤的作用。中华妇产科杂志。1999，34(3)：165-167。
[11] Hoganson DK, Batra RK, Olsen JC, et al.. Comparison of the effects of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma. Cancer Res. 1996 Mar 15; 56 (6): 1315-23.
[12] Coustere C, Mentre F, Sommadossi JP, et al. A mathematical model of the kinetics of 5-fluorouracil and its metabolites in cancer patients. Cancer Chemother Pharmacol. 1991; 28(2):123-9.
[13] Joki T, Nakamura M, Ohno T. Activation of the radiosensitive EGR-1 promoter induces expression of the herpes simplex virus thymidine kinase gene and sensitivity of human glioma cells to ganciclovir. Hum Gene Ther 1995 Dec; 6(12):1507-13.
[14] Hanna E, Zhang X, Woodlis J, et al. Intramuscular electroporation delivery of IL-12 gene for treatment of squamous cell carcinoma located at distant site. Cancer Gene Ther. 2001 Mar;8(3):151-7.
[15] Corban-Wilhelm H, Hull WE, Becker G, et al. Cytosine deaminase and thymidine kinase gene therapy in a Dunning rat prostate tumour model: absence of bystander effects and characterisation of 5-fluorocytosine metabolism with 19F-NMR spectroscopy. Gene Ther. 2002 Dec; 9(23): 1564-75.
[16] Erbs P, Regulier E, Kintz J, et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res 2000 Jul 15; 60(14):3813-22
[17]Mullen CA, Kilstrup M, Blaese RM. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):33-7.
[18] Erbs P, Regulier E, Kintz J, et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res 2000 Jul 15; 60(14):3813-22
[19] Pow EH, McMillan AS, Leung WK, et al. Oral health condition in southern Chinese after radiotherapy for nasopharyngeal carcinoma: extent and nature of the problem. Oral Dis. 2003 Jul;9(4):196-202.
[20] Miyagi T, Koshida K, Hori 0, et al. Gene therapy for prostate cancer using the cytosine deaminase/uracil phosphoribosyltransferase suicide system. J Gene Med. 2003 Jan; 5 (1) : 30-7.
[21] Wang WJ, Tai CK, Kasahara N, et al. Highly efficient and tumor-restricted gene transfer to malignant gliomas by replication-competent retroviral vectors. Hum Gene Ther. 2003 Jan 20: 14 (2) : 117-27.
[22] 冯跃，赵军，黄盛东，等。CD、TK双自杀基因对消化道肿瘤细胞的体外抑制作用。中华国际医学杂志。2002，2 (4)：314-317
[23] Sung MW, Yeh HC, Thung SN, et al Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: results of a phase I clinical trial. Mol Ther. 2001 Sep; 4 (3) : 182-91.
[24] Griscelli F, Opolon P, Saulnier P, et al. Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients. Gene Ther. 2003 Mar; 10 (5) : 386-95.
[25] Xie Yunjie, Gilbert JD, Kim JH, et al. Efficacy of adenovirus-mediated CD/5-FC and HSV-1 thymidine kinase/ganciclovir suicide gene therapies concomitant with p53 gene therapy. Clin Cancer Res. 1999 Dec; 5 (12) : 4224-32.
[26] 刘晓霞，姜伟，姚明等GE7导入系统介导Ⅰ型单纯疱疹病毒胸腺嘧啶核苷激酶基因联合52FU治疗卵巢癌的研究。现代妇产科进展。2004，13 (6)：413-415。
[27] 姚远，彭芝兰，王和等。胞嘧啶脱氨酶基因联合52氟胞嘧啶对卵巢癌裸鼠移植瘤的抑制作用。中华妇产科杂志。2002，37 (4)：195-197。
[28] Kievit E, Bershad E, Ng E, et al. Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. Cancer Res. 1999 Apr 1; 59 (7) : 1417-21.
[29] Chung-Faye GA, Chen MJ, Green NK, et al. In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. Gene Ther. 2001 Oct; 8 (20) : 1547-54.
[30]. Erbs P, Regulier E, Kintz J, et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res. 2000 Jul 15; 60 (14) : 3813-22.
[31] Rogulski KR, Zhang K, Kolozsvary A, et al. Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy. Clin Cancer Res 1997 Nov; 3 (11) : 2081-8
[32] Sukhatme VP, Cao XM, Chang LC, et al. . A zinc finger-encoding gene coregulated with c-fos during growth and differentiation, and after cellular depolarization. Cell 1988 Apr 8; 53 (1) : 37-43
[33] Datta R, Rubin E, Sukhatme V, et al. . Ionizing radiation activates transcription of the EGR1 gene via CArG elements. Proc Natl Acad Sci U S A. 1992 Nov 1; 89 (21) : 10149-53.
[34]. Weichselbaum RR, Hallahan DE, Beckett MA, et al. Gene therapy targeted by radiation preferentially radiosensitizes tumor cells. Cancer Res. 1994 Aug 15; 54 (16) : 4266-9.
[35]. Kawashita Y, Ohtsuru A, Kaneda Y, et al. Regression of hepatocellular carcinoma in vitro and in vivo by radiosensitizing suicide gene therapy under the inducible and spatial control of radiation. Hum Gene Ther. 1999 Jun 10; 10 (9) : 1509-19.
[36] 魏道严，戴冰冰，陈诗书。放射诱导经Egr-1启动子调控的腺病毒介导CDglyTK基因的肿瘤靶向表达。中华医学杂志。2001，81 (16)：999-1003
[1] 林仲秋．宫颈癌治疗进展．广东医学，2004，25(2)：113-115
[2] 陈忠东，胡泳，曾宪端．卵巢移位及阴道延长术在宫颈癌治疗中的作用．中国 肿瘤临床，2000，27(4)：308-309．
[3] Sakuragi N, Takeda N, Hareyama H, etal. A multivariate analysis of blood vessel and lymph vessel invasion as predictors of ovarian and lymph mode metastases in patient with cervical carcinoma [J]. Cancer, 2000, 88: 2578-2583.
[4] Toman J, Feyereisl G, Zamecnik J, et al. A safe site for transpositation of ovaries in radical hysterectomy for cervical carcinoma [J]. Ceska Gynekol, 2001, 66: 184-186.
[5] 倪立洲．卵巢移植及功能保护在宫颈癌治疗中的作用探讨．现代中西医结合杂志，2005，14(15)：2035-2036．
[6] Pecorelli S. FIGO annual report on the results of treatment in gynecological cancer. (Vol. 23). Spain: BookPrint, SL, 1998. 5.
[7] 罗刚，郑成位，单锦露，等．~(252)锎中子腔内后装治疗宫颈癌的临床观察．中华妇产科杂志，2001，36(12)：742．
[8] Fellner C, Potter R, Knocke TH, et al. Comparison of radiography and computed tomography-based treatment planning in cervix cancer in brachytherapy with specific attention to some quality assurance aspects [J]. Radiother Oncl, 2001, 58 (1) : 53-62.
[9] Krempien RC, Daeuber S, Hensley FW, et al. Image fusion of CT and MRI data enables improved target volume definition in 3D-brachytherapy treatment planning[J], brachytherapy, 2003, 2 (3) : 164-171.
[10] Wachter-Gerstner N, Wachter S, Reinstadler E, et al. Bladder and rectum dose define from MRI based treatment planning for cervix cancer brachytherapy: comparison of dose-volume histograms for organ contours and organ wall, comparison with ICRU rectum and bladder reference point[J]. Radiother Oncol, 2003, 68 (3) : 269-276.
[11] Mutic S, Grigsby PW, Low DA, et al. PET-guided three-dimensional treatment planning of intracavitary gynecologic implants[J]. Int J Radiat Oncol Biol Phys, 2002, 52 (4) : 1104-1110.
[12] 刘德梅，朱向华．立体定向放射治疗宫颈癌的近期疗效观察．肿瘤研究与临床．2004，16(3)：207-208．
[13] 关玉兰，龙再秋，王伊洵．组织间插植放疗治疗外生型宫颈癌疗效探讨．中国实用妇科与产科杂志，2003，19(12)：745-746．
[14] Ferrandina G. Scambia G, Fagotti A, et al. Immunoradiometric and immunohistochemical analysis of Cathepsin D in ovarian cancer: lack of association with clinical outcome. Br J Cancer. 1998Dec, 78 (12) : 1645-52.
[15] Kim K, Chie EK, Wu HG, et al. Efficacy of paclitaxel and carboplatin as a regimen for postoperative concurrent chemoradiotherapy of high risk uterine cervix cancer. Gynecol Oncol, 2005 Dec, [Epub ahead of print].
[16] Borysiewicz LK, Fiander A, Nimako M, et al. A recombinant vaccinia virus encoding human papilloma virus types 16 and18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet, 1996, 347 (9014) : 1523.
[17] Van Driel WJ, Ressing ME, Kenter GG, et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of aphase Ⅰ～Ⅱ trial. EurJCancer, 1999, 35 (6) : 946.
[18] Muder spachL, Wilczynski S, Roman L, et al. A phase I trial of a human papillomavirus(HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV16 positive. ClinCancerRes, 2000, 6 (9) : 3406.
[19] Santin AD, Bellone S, Gokden M, et al. Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer. N Engl J Med, 2002, 346 (22) : 1752.
[20] Tanaka M, Inase N, Miyake S, et al. Neuron specific enolase promoter for suicide gene therapy in small cell lung carcinoma. Anti cancer Res, 2001, 21 (1A) : 291-294.
[21] Sethi N, Palefsky J. Treatment of human papilloma virus(HPV) type16-infected cells using herpes simplex virus typel thymidine kinase-mediated gene therapy transcriptionally regulated by the HPVE2 protein. HumGeneTher, 2003, 14 (1) : 45 57.
[22] Street D, Kaufmann AM, Vaughan A, et al. Interferon-gamma enhances susceptibility of cervical cancer cells to lysis by tumor-specific cytotoxic T cells. Gynecol Oncol, 1997, 65 (2) : 265 272.
[23] Ahn WS, Han YJ, Bae SM, et al. Differential suppression of human cervical cancer cell growth by adenovirus delivery of p53 in vitro: arrest phase of cell cycle is dependent on cell line. Jpn J Cancer Res, 2002, 93 (9) : 1012 1019.
[24] Buck AC, Shen C, Schirmeister H, et al. Liposomal delivery of antisene oliginucleotides for efficient down regulation of BCL2 and induced of apoptosis. Cancer Biother Radiopharm, 2003, 312 (3) : 585-591.
[25] 陈星，糜若然．反义治疗在宫颈癌中的研究．国外医学妇产科学分册，2005，32(4)：220-223．
[26] Kim HS, Shiraki K, Park SH. Expression of survivin in CIN and invasive squamous cell carcinoma of uterine cervix. Anticancer Res, 2002, 22 (2A) : 805-808.
[27] 王宏伟，陆志冲．电化学治疗宫颈癌32例观察报告．BIOMAGNETISM，2004，34-35．
[28] Green J, Kirwan J, Tiemey J, et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev. 2005 Jul 20; (3) : CD002225.
[29] Kim K, Chie EK, Wu HG, et al. Efficacy of paclitaxel and carboplatin as a regimen for postoperative concurrent chemoradiotherapy of high risk uterine cervix cancer. Gynecol Oncol. 2005 Dec 2; [Epub ahead of print].
[30] 黎婧琳．43℃微波热疗配合放射治疗宫颈癌的疗效观察．华夏医学，2004，6(17)：951-952．
[31] 耿进朝，张勇，李明山，等．超选择性TACE和静脉化疗治疗宫颈癌的临床应用．中国临床医学影像杂志，2004，15(3)：155-157．